The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy
B7x is a B7-family ligand with suppressive effects on effector T cells. Here the authors show that tumor-expressed B7x promotes the conversion of conventional CD4+ T cells into regulatory T cells within the tumor microenvironment to promote immune evasion and resistance to anti-CTLA-4 therapy.
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-05-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-022-30143-8 |
| _version_ | 1818007199554732032 |
|---|---|
| author | Peter John Marc C. Pulanco Phillip M. Galbo Yao Wei Kim C. Ohaegbulam Deyou Zheng Xingxing Zang |
| author_facet | Peter John Marc C. Pulanco Phillip M. Galbo Yao Wei Kim C. Ohaegbulam Deyou Zheng Xingxing Zang |
| author_sort | Peter John |
| collection | DOAJ |
| description | B7x is a B7-family ligand with suppressive effects on effector T cells. Here the authors show that tumor-expressed B7x promotes the conversion of conventional CD4+ T cells into regulatory T cells within the tumor microenvironment to promote immune evasion and resistance to anti-CTLA-4 therapy. |
| first_indexed | 2024-04-14T05:12:31Z |
| format | Article |
| id | doaj.art-60920b90f3ff4389949136f7a8e26dd2 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-14T05:12:31Z |
| publishDate | 2022-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-60920b90f3ff4389949136f7a8e26dd22022-12-22T02:10:29ZengNature PortfolioNature Communications2041-17232022-05-0113111510.1038/s41467-022-30143-8The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapyPeter John0Marc C. Pulanco1Phillip M. Galbo2Yao Wei3Kim C. Ohaegbulam4Deyou Zheng5Xingxing Zang6Department of Microbiology & Immunology, Albert Einstein College of MedicineDepartment of Microbiology & Immunology, Albert Einstein College of MedicineDepartment of Genetics, Albert Einstein College of MedicineDepartment of Microbiology & Immunology, Albert Einstein College of MedicineDepartment of Microbiology & Immunology, Albert Einstein College of MedicineDepartment of Genetics, Albert Einstein College of MedicineDepartment of Microbiology & Immunology, Albert Einstein College of MedicineB7x is a B7-family ligand with suppressive effects on effector T cells. Here the authors show that tumor-expressed B7x promotes the conversion of conventional CD4+ T cells into regulatory T cells within the tumor microenvironment to promote immune evasion and resistance to anti-CTLA-4 therapy.https://doi.org/10.1038/s41467-022-30143-8 |
| spellingShingle | Peter John Marc C. Pulanco Phillip M. Galbo Yao Wei Kim C. Ohaegbulam Deyou Zheng Xingxing Zang The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy Nature Communications |
| title | The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy |
| title_full | The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy |
| title_fullStr | The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy |
| title_full_unstemmed | The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy |
| title_short | The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy |
| title_sort | immune checkpoint b7x expands tumor infiltrating tregs and promotes resistance to anti ctla 4 therapy |
| url | https://doi.org/10.1038/s41467-022-30143-8 |
| work_keys_str_mv | AT peterjohn theimmunecheckpointb7xexpandstumorinfiltratingtregsandpromotesresistancetoantictla4therapy AT marccpulanco theimmunecheckpointb7xexpandstumorinfiltratingtregsandpromotesresistancetoantictla4therapy AT phillipmgalbo theimmunecheckpointb7xexpandstumorinfiltratingtregsandpromotesresistancetoantictla4therapy AT yaowei theimmunecheckpointb7xexpandstumorinfiltratingtregsandpromotesresistancetoantictla4therapy AT kimcohaegbulam theimmunecheckpointb7xexpandstumorinfiltratingtregsandpromotesresistancetoantictla4therapy AT deyouzheng theimmunecheckpointb7xexpandstumorinfiltratingtregsandpromotesresistancetoantictla4therapy AT xingxingzang theimmunecheckpointb7xexpandstumorinfiltratingtregsandpromotesresistancetoantictla4therapy AT peterjohn immunecheckpointb7xexpandstumorinfiltratingtregsandpromotesresistancetoantictla4therapy AT marccpulanco immunecheckpointb7xexpandstumorinfiltratingtregsandpromotesresistancetoantictla4therapy AT phillipmgalbo immunecheckpointb7xexpandstumorinfiltratingtregsandpromotesresistancetoantictla4therapy AT yaowei immunecheckpointb7xexpandstumorinfiltratingtregsandpromotesresistancetoantictla4therapy AT kimcohaegbulam immunecheckpointb7xexpandstumorinfiltratingtregsandpromotesresistancetoantictla4therapy AT deyouzheng immunecheckpointb7xexpandstumorinfiltratingtregsandpromotesresistancetoantictla4therapy AT xingxingzang immunecheckpointb7xexpandstumorinfiltratingtregsandpromotesresistancetoantictla4therapy |